Enhancement of the antineoplastic effect of anticarcinogens on benzo[a]pyrene-treated Wistar rats, in relation to their number and biological activity

dc.contributor.authorKallistratos, G.en
dc.contributor.authorEvangelou, A.en
dc.contributor.authorAgnantis, N.en
dc.contributor.authorFasske, E.en
dc.contributor.authorKarkabounas, S.en
dc.contributor.authorDonos, A.en
dc.date.accessioned2015-11-24T19:19:11Z
dc.date.available2015-11-24T19:19:11Z
dc.identifier.issn0304-3835-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/21939
dc.rightsDefault Licence-
dc.subjectAnimalsen
dc.subjectAntineoplastic Agents/*pharmacologyen
dc.subjectAscorbic Acid/*pharmacologyen
dc.subjectBenzo(a)pyrene/*antagonists & inhibitorsen
dc.subjectDrug Screening Assays, Antitumoren
dc.subjectDrug Synergismen
dc.subjectFemaleen
dc.subjectNeoplasms, Experimental/chemically induced/mortality/*prevention & controlen
dc.subjectRatsen
dc.subjectRats, Wistaren
dc.subjectSelenium/*pharmacologyen
dc.subjectVitamin E/*pharmacologyen
dc.titleEnhancement of the antineoplastic effect of anticarcinogens on benzo[a]pyrene-treated Wistar rats, in relation to their number and biological activityen
heal.abstractNaturally occurring anticarcinogens, such as vitamins C and E, and the microelement selenium were found to inhibit the induction of benzo[a]pyrene-induced malignant tumors in Wistar rats to various extends. The antineoplastic effect of the tested anticarcinogens is gradually increased according to the number of inhibitors selected. To date the maximum action against malignancy is manifested by use of the above three inhibitors. In the group of rats receiving vitamins C, E and selenium, the prolongation of life induced by adding more than one anticarcinogen to the treatment regime reached, and in some cases surpassed, the normal life expectancy of the rats. It is expected that by adding even more anticarcinogens, the antineoplastic potency (Ap) of the inhibitors will be further improved. These results encouraged us to conduct a clinical trial in terminal human cancer cases, in conjunction with the usual treatments of surgery or chemotherapy and irradiation.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/8050086-
heal.identifier.secondaryhttp://ac.els-cdn.com/030438359490006X/1-s2.0-030438359490006X-main.pdf?_tid=7da7d2455cea2abee415b44d8d6cf8cc&acdnat=1332928480_b881ee68ff95eb399620a4ea402a2a2f-
heal.journalNameCancer Letten
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate1994-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Φόρτωση...
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή: